1. Pink Sheet
  2. >>Product Reviews

Analyzing the Evidence For The Convalescent Plasma EUA

 
• By Derrick Gingery

The justification President Trump used is not directly mentioned in the decision memo, but other data suggests a less-than-overwhelming case for granting emergency use authorization.

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
The FDA used several kinds of evidence to make its decision on the convalescent plasma EUA. • Source: Shutterstock

US Food and Drug Administration officials agreed there is enough evidence that convalescent plasma “may be effective” and warranted an emergency use authorization, but argued more definitive data is necessary to pinpoint efficacy and the optimal populations that could benefit.

In a clinical memo, agency officials outlined the different and sometimes conflicting evidence that fed into its decision to grant an emergency use authorization for convalescent plasma as a coronavirus treatment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 
• By Laura Helbling

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.